Have a feature idea you'd love to see implemented?
Let us know!
MBRX Moleculin Biotech Inc
Price (delayed)
$2.83
Market cap
$8.5M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$11.74
Enterprise value
-$519,637
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses.
Highlights
MBRX's debt is down by 21% year-on-year and by 7% since the previous quarter
The EPS has grown by 13% year-on-year
The company's equity has shrunk by 79% YoY and by 58% QoQ
MBRX's quick ratio has dropped by 73% year-on-year and by 11% since the previous quarter
Key stats
What are the main financial stats of MBRX
Market
Valuations
Earnings
Shares outstanding
3M
Market cap
$8.5M
Enterprise value
-$519,637
Price to earnings (P/E)
N/A
Price to book (P/B)
0.97
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$30.15M
EBITDA
-$30.02M
Free cash flow
-$24.27M
Per share
Balance sheet
Liquidity
EPS
-$11.74
Free cash flow per share
-$6.53
Book value per share
$2.92
Revenue per share
$0
TBVPS
$3.3
Total assets
$23.39M
Total liabilities
$15.92M
Debt
$390,000
Equity
$7.48M
Working capital
$6.01M
Debt to equity
0.05
Current ratio
2.08
Quick ratio
1.68
Net debt/EBITDA
0.3
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-102.2%
Return on equity
-165.6%
Return on invested capital
N/A
Return on capital employed
-169.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MBRX stock price
How has the Moleculin Biotech stock price performed over time
Intraday
5.99%
1 week
-8.41%
1 month
5.99%
1 year
-63.86%
YTD
-78.03%
QTD
-0.35%
Financial performance
How have Moleculin Biotech's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$28.92M
Net income
-$30.15M
Gross margin
N/A
Net margin
N/A
MBRX's net income is down by 20% since the previous quarter and by 15% year-on-year
MBRX's operating income is down by 4.3% from the previous quarter and by 4.2% YoY
Growth
What is Moleculin Biotech's growth rate over time
Valuation
What is Moleculin Biotech stock price valuation
P/E
N/A
P/B
0.97
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 13% year-on-year
The company's equity has shrunk by 79% YoY and by 58% QoQ
MBRX's price to book (P/B) is 25% lower than its 5-year quarterly average of 1.3 but 21% higher than its last 4 quarters average of 0.8
Efficiency
How efficient is Moleculin Biotech business performance
The company's return on equity has shrunk by 173% YoY and by 65% QoQ
Moleculin Biotech's return on assets has shrunk by 90% YoY and by 36% QoQ
Dividends
What is MBRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MBRX.
Financial health
How did Moleculin Biotech financials performed over time
Moleculin Biotech's total assets is 47% higher than its total liabilities
The total liabilities has surged by 102% since the previous quarter
MBRX's quick ratio has dropped by 73% year-on-year and by 11% since the previous quarter
MBRX's debt is 95% smaller than its equity
The debt to equity has soared by 150% from the previous quarter
The company's equity has shrunk by 79% YoY and by 58% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.